Estimating benefit from dose dense adjuvant chemotherapy for early breast cancer in the PANTHER randomized phase 3 trial

被引：0
|
作者：
Matikas, Alexios
Gnant, Michael
Johansson, Hemming
Untch, Michael
Tsiknakis, Nikolaos
Greil, Richard
Loibl, Sibylle
Foukakis, Theodoros
Bergh, Jonas C. S.
机构：
[1] Karolinska Inst, Stockholm, Sweden
[2] Karolinska Univ Hosp, Stockholm, Sweden
[3] Med Univ Vienna, Ctr Comprehens Canc, Vienna, Austria
[4] Helios Klinikum Berlin Buch, Berlin, Germany
[5] Paracelsus Med Univ, Canc Cluster Salzburg, Ctr Clin Canc & Immunol Trials, Med Dept 3,Salzburg Canc Res Inst, Salzburg, Austria
[6] GBG Forsch GmbH, Neu Isenburg, Germany
[7] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden
[8] Karolinska Univ Hosp, Karolinska Comprehens Canc Ctr, Breast Canc Ctr, Canc Theme, Stockholm, Sweden
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
521
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Safety and tolerability of adjuvant dose dense chemotherapy in elderly patients with node-positive early breast cancer
    Karavasilis, Vasilios
    Pectasides, Dimitrios G.
    Papadimitriou, Christos A.
    Gogas, Helen
    Kouvatseas, George
    Christodoulou, Christos
    Koutras, Angelos
    Pentheroudakis, George E.
    Linardou, Helena
    Razis, Evangella
    Aravantinos, Gerasimos
    Dimopoulos, Meletios A.
    Fountzilas, George
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [42] Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study
    Eva Blondeaux
    Matteo Lambertini
    Andrea Michelotti
    Benedetta Conte
    Marco Benasso
    Chiara Dellepiane
    Claudia Bighin
    Simona Pastorino
    Alessia Levaggi
    Alessia D’ Alonzo
    Francesca Poggio
    Giulia Buzzatti
    Chiara Molinelli
    Piero Fregatti
    Sergio Bertoglio
    Francesco Boccardo
    Lucia Del Mastro
    British Journal of Cancer, 2020, 122 : 1611 - 1617
  • [43] Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study
    Blondeaux, Eva
    Lambertini, Matteo
    Michelotti, Andrea
    Conte, Benedetta
    Benasso, Marco
    Dellepiane, Chiara
    Bighin, Claudia
    Pastorino, Simona
    Levaggi, Alessia
    D' Alonzo, Alessia
    Poggio, Francesca
    Buzzatti, Giulia
    Molinelli, Chiara
    Fregatti, Piero
    Bertoglio, Sergio
    Boccardo, Francesco
    Del Mastro, Lucia
    BRITISH JOURNAL OF CANCER, 2020, 122 (11) : 1611 - 1617
  • [44] ADJUVANT HORMONAL CHEMOTHERAPY IN EARLY BREAST-CANCER - EARLY RESULTS FROM A CONTROLLED TRIAL
    SENANAYAKE, F
    LANCET, 1984, 2 (8412): : 1148 - 1149
  • [45] Development of individual adjuvant chemotherapy benefit estimating program for breast cancer patients management
    Rouzier, R.
    Stevens, D.
    Bonneau, C.
    Falcou, M-C
    Hequet, D.
    Pierga, J-Y
    Lerebours, F.
    CANCER RESEARCH, 2016, 76
  • [46] A DECISION ANALYTIC MODEL ESTIMATING THE BENEFIT OF ADJUVANT CHEMOTHERAPY IN PATIENTS WITH BREAST-CANCER
    MOSKOWITZ, AJ
    ECKMAN, MH
    PARKINSON, DR
    ROBERT, NJ
    PAUKER, SG
    BREAST CANCER RESEARCH AND TREATMENT, 1986, 8 (01) : 94 - 94
  • [47] Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 x 2 factorial, randomised phase 3 trial
    Del Mastro, Lucia y
    De Placido, Sabino
    Bruzzi, Paolo
    De Laurentiis, Michele
    Boni, Corrado
    Cavazzini, Giovanna
    Durando, Antonio
    Turletti, Anna
    Nistico, Cecilia
    Valle, Enrichetta
    Garrone, Ornella
    Puglisi, Fabio
    Montemurro, Filippo
    Barni, Sandro
    Ardizzoni, Andrea
    Gamucci, Teresa
    Colantuoni, Giuseppe
    Giuliano, Mario
    Gravina, Adriano
    Papaldo, Paola
    Bighin, Claudia
    Bisagni, Giancarlo
    Forestieri, Valeria
    Cognetti, Francesco
    LANCET, 2015, 385 (9980): : 1863 - 1872
  • [48] Cyclophosphamide-Free Adjuvant Chemotherapy for Ovarian Protection in Young Women With Breast Cancer: A Randomized Phase 3 Trial
    Yu, Ke-Da
    Ge, Jing-Yu
    Liu, Xi-Yu
    Mo, Miao
    He, Min
    Shao, Zhi-Ming
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (10): : 1352 - 1359
  • [49] Dose-dense adjuvant chemotherapy in early-stage breast cancer patients: End-of-study results from a randomised, phase III trial of the Gruppo Italiano Mammella GIM)
    Del Mastro, L.
    Poggio, F.
    Blondeaux, E.
    de Placido, S.
    Giuliano, M.
    De laurentiis, M.
    Bisagni, G.
    Cantore, M.
    Turletti, A.
    Nistico, C.
    Urracci, Y.
    Garrone, O.
    Bighin, C.
    Mansutti, M.
    Montemurro, F.
    Colantuoni, G.
    Lambertini, M.
    Boni, L.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S599 - S600
  • [50] Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2)
    Moebus, Volker
    Lueck, Hans-Joachim
    Ladda, Ekkehart
    Klare, Peter
    Schmidt, Marcus
    Schneeweiss, Andreas
    Grischke, Eva-Maria
    Wachsmann, Grischa
    Forstbauer, Helmut
    Untch, Michael
    Marme, Frederik
    Blohmer, Jens-Uwe
    Jackisch, Christian
    Huober, Jens
    Stickeler, Elmar
    Reinisch, Mattea
    Link, Theresa
    Sinn, Bruno, V
    Janni, Wolfgang
    Denkert, Carsten
    Furlanetto, Jenny
    Engels, Knut
    Solbach, Christine
    Schmatloch, Sabine
    Rey, Julia
    Burchardi, Nicole
    Loibl, Sibylle
    EUROPEAN JOURNAL OF CANCER, 2021, 156 : 138 - 148
12345